REGN
Regeneron Pharmaceuticals
Is REGN Halal?
Biopharmaceutical — life-saving medicine development.
What You Should Know
Regeneron develops monoclonal antibody therapies. Its March 2026 Form 10-Q reports $40,868.8 million of assets, $2,706.2 million of interest-bearing debt including finance leases, $2,970.6 million of cash and restricted cash, $15,577.1 million of marketable securities, $5,731.0 million of receivables and $3,605.4 million of quarterly revenue. Debt/assets is 6.62%, liquidity/assets is 45.38%, receivables-plus-cash/assets is 21.29%, and disclosed interest income is 5.09% of revenue; the liquidity and income screens fail under the examined limits despite the permissible core business.
⚠️ Concerns
- •Research involving animal-derived components
- •Marketable securities are a material asset balance
- •Interest income exceeds the examined 5% FTSE income limit
- •Collaboration, licensing and clinical-research structures require review
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-14.
2,706.2 / 40,868.8
18,547.7 / 40,868.8
8,701.6 / 40,868.8
183.5 / 3,605.4
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 45.38%, above the examined 33.333% limit, and disclosed interest income is 5.09% of revenue, above the examined 5% FTSE income limit.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 45.38%, above the examined MSCI 33.33% limit; debt/assets is 6.62% and receivables-plus-cash/assets is 21.29%.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is above the examined Malaysia 33% limit; this is a calculation against SAC ratios, not an official classification.
- Financial
- Not calculated
- Overall
- Fails
A properly licensed and reproducible historical market-cap series is not stored; the financial screen failure is independently documented.
Business-activity disclosure
Regeneron develops and commercializes biopharmaceutical products and collaborates with pharmaceutical partners. Healthcare products are generally permissible, while research materials, licensing, collaborations and investment income require qualitative review.
Limitation: The filing does not provide a universal prohibited-activity numerator for all product, collaboration, research and licensing activities.
Purification
Regeneron discloses $183.5 million of interest income, but does not disclose a complete prohibited-activity numerator; no definitive purification percentage is invented.
Inputs, assumptions and primary sources
- Amounts are USD millions from Regeneron's March 31, 2026 Form 10-Q.
- Interest-bearing debt is $1,986.2 million of long-term debt plus $720.0 million of finance lease liabilities.
- Cash and cash equivalents are $2,962.6 million and restricted cash is $8.0 million. Marketable securities total $15,577.1 million across current and noncurrent balances and are included as interest-bearing securities.
- Accounts receivable, net are $5,731.0 million.
- Total revenue is $3,605.4 million for the three months ended March 31, 2026; disclosed interest income is $183.5 million.
- Pharmaceutical products, collaboration profits, research and licensing structures are not reduced to a universal prohibited-revenue numerator.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →